CASI · Casi Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $10.21M | $8.57M | $9.06M | - | $8.11M | $7.16M | $5.74M | - | $4.24M |
| Cost of Revenue | - | $4.25M | $3.55M | $3.76M | - | $3.42M | $2.98M | $2.36M | - | $1.83M |
| Gross Profit | - | $5.97M | $4.18M | $5.30M | - | $4.70M | $4.18M | $3.38M | - | $2.41M |
| R&D | - | $3.90M | $3.85M | $3.99M | - | $2.90M | $2.25M | $5.26M | - | $2.80M |
| SG&A | - | $4.85M | $5.52M | $5.33M | - | $5.26M | $5.42M | $5.50M | - | $5.35M |
| Total Operating Expenses | - | $12.32M | $12.77M | $12.59M | - | $11.59M | $15.14M | $21.33M | - | $22.90M |
| D&A | - | - | - | $92.0K | - | - | - | $146.0K | - | - |
| Operating Income | - | ($6.35M) | ($7.75M) | ($7.29M) | - | ($6.89M) | ($7.98M) | ($15.60M) | - | ($18.66M) |
| Interest Expense | - | - | - | - | - | $900 | $1.0K | $1.00M | - | $1.2K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($5.20M) | ($7.68M) | ($8.60M) | - | ($10.22M) | ($6.95M) | ($13.88M) | - | ($16.95M) |
| EPS - Basic | - | ($0.73) | ($0.56) | ($0.06) | - | - | - | - | - | - |
| EPS - Diluted | - | ($0.73) | ($0.50) | ($0.11) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $47.11M | $26.74M | $18.86M | $29.26M | $38.70M | $53.13M | $60.36M | $68.12M | $57.06M | $74.59M |
| Accounts Receivable | $12.97M | $12.56M | $10.26M | $10.09M | $9.80M | $5.42M | $5.77M | $5.84M | $4.64M | $4.08M |
| Inventory | $6.14M | $5.77M | $5.79M | $3.72M | $1.91M | $1.73M | $3.48M | $2.99M | $1.36M | $720.0K |
| Accounts Payable | $3.29M | $3.10M | $4.60M | $7.17M | $4.79M | $6.32M | $5.52M | $5.74M | $3.67M | $2.70M |
| Current Assets | $73.42M | $55.61M | $42.28M | $52.70M | $61.97M | $71.96M | $83.50M | $89.01M | $74.03M | $83.28M |
| Total Assets | $96.23M | $127.91M | $118.86M | $129.56M | $138.30M | $136.27M | $144.53M | $148.09M | $127.73M | $134.24M |
| Current Liabilities | $17.00M | $29.75M | $13.18M | $13.87M | $13.19M | $9.96M | $10.02M | $9.97M | $7.98M | $5.55M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $181.0K |
| Total Liabilities | $29.30M | $44.69M | $29.25M | $30.85M | $30.34M | $26.76M | $27.03M | $25.90M | $24.16M | $21.44M |
| Stockholders' Equity | $44.57M | $61.71M | $66.94M | $74.99M | $84.50M | $86.61M | $94.80M | $100.03M | $81.54M | $91.53M |
| Retained Earnings | ($637.16M) | ($624.86M) | ($620.57M) | ($613.63M) | ($605.64M) | ($599.97M) | ($590.26M) | ($583.84M) | ($570.50M) | ($556.81M) |
Cash Flow
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($4.24M) | - | - | - | ($8.00M) | - | - |
| Investing Cash Flow | - | - | - | ($2.29M) | - | - | - | ($12.07M) | - | - |
| Financing Cash Flow | - | - | - | ($3.00M) | - | - | - | $31.19M | - | - |
| CapEx | - | - | - | $2.29M | - | - | - | $981.0K | - | - |
| Free Cash Flow | - | - | - | ($6.53M) | - | - | - | ($8.98M) | - | - |
Ratios
| Metric | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 58.4% | 48.8% | 58.5% | - | 57.9% | 58.4% | 58.9% | - | 56.9% |
| Operating margin | - | -62.2% | -90.4% | -80.4% | - | -85.0% | -111.4% | -271.9% | - | -439.9% |
| EBITDA margin | - | - | - | -79.4% | - | - | - | -269.4% | - | - |
| Net margin | - | -50.9% | -89.6% | -94.9% | - | -126.0% | -97.0% | -242.0% | - | -399.6% |
| Free cash flow margin | - | - | - | -72.0% | - | - | - | -156.6% | - | - |
| FCF / Net income | - | - | - | 0.76 | - | - | - | 0.65 | - | - |
| R&D / Revenue | - | 38.2% | 44.9% | 44.1% | - | 35.7% | 31.5% | 91.7% | - | 66.1% |
| SG&A / Revenue | - | 47.5% | 64.4% | 58.8% | - | 64.8% | 75.7% | 95.9% | - | 126.0% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -4.1% | -6.5% | -6.6% | - | -7.5% | -4.8% | -9.4% | - | -12.6% |
| Return on equity | - | -8.4% | -11.5% | -11.5% | - | -11.8% | -7.3% | -13.9% | - | -18.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.32 | 1.87 | 3.21 | 3.80 | 4.70 | 7.23 | 8.33 | 8.93 | 9.28 | 14.99 |
| Quick ratio | 3.96 | 1.68 | 2.77 | 3.53 | 4.56 | 7.05 | 7.99 | 8.63 | 9.11 | 14.86 |
| Cash ratio | 2.77 | 0.90 | 1.43 | 2.11 | 2.94 | 5.34 | 6.02 | 6.83 | 7.15 | 13.43 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -7657.8x | -7978.0x | -15.6x | - | -15550.0x |
| Equity multiplier | 2.16 | 2.07 | 1.78 | 1.73 | 1.64 | 1.57 | 1.52 | 1.48 | 1.57 | 1.47 |
| Liabilities / Assets | 0.30 | 0.35 | 0.25 | 0.24 | 0.22 | 0.20 | 0.19 | 0.17 | 0.19 | 0.16 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.08 | 0.07 | 0.07 | - | 0.06 | 0.05 | 0.04 | - | 0.03 |
| Inventory turnover | - | 0.74 | 0.61 | 1.01 | - | 1.98 | 0.86 | 0.79 | - | 2.54 |
| Days sales outstanding | - | 449d | 437d | 406d | - | 244d | 294d | 371d | - | 351d |
| Days inventory outstanding | - | 496d | 595d | 361d | - | 184d | 425d | 463d | - | 144d |
| Days payable outstanding | - | 266d | 473d | 696d | - | 676d | 676d | 889d | - | 539d |
| Cash conversion cycle | - | 679d | 559d | 71d | - | -247d | 44d | -54d | - | -44d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 25.9% | 19.7% | 58.0% | - | 91.2% | 168.1% | 68.4% | - | 52.2% |
| Revenue CAGR (3y) | - | 54.2% | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | 27.1% | 0.0% | 57.0% | - | 94.5% | 2614.3% | 1632.3% | - | 1636.7% |
| Operating income growth (YoY) | - | 7.8% | 2.9% | 53.3% | - | 63.1% | 10.2% | -77.8% | - | -75.3% |
| Net income growth (YoY) | - | 49.1% | -10.6% | 38.1% | - | 39.7% | 20.1% | -64.5% | - | -75.8% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 27.3% | - | - | - | -93.8% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -47.3% | -28.7% | -29.4% | -25.0% | 3.6% | -5.4% | 49.7% | 42.2% | 11.7% | 13.9% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing CASI Pharmaceuticals against the 5 most active filers in the same SIC group.